CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26)

This study explores the therapeutic potential of targeting CXCR2 in patients afflicted with ponatinib-resistant chronic myeloid leukemia (CML). Ponatinib, a third-generation tyrosine kinase inhibitor (TKI), was initially designed for treating patients with CML harboring the T315I mutation. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ji-Hea, Kang, Ka-Won, Park, Yong, Kim, Byung Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692791/
https://www.ncbi.nlm.nih.gov/pubmed/38045173
http://dx.doi.org/10.1016/j.heliyon.2023.e22091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692791/
https://www.ncbi.nlm.nih.gov/pubmed/38045173
http://dx.doi.org/10.1016/j.heliyon.2023.e22091

Ejemplares similares